Skip to content

The psychological characteristics and neural basis of rosacea

The psychological characteristics and neural basis of rosacea

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068395
Enrollment
Unknown
Registered
2023-02-17
Start date
2023-02-17
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Interventions

Rosacea group:N/A
Healthy control group:N/A

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Experiment group: 1. Patients diagnosed with rosacea confirmed the National Board of Rosacea Specialists diagnostic criteria (2017 edition); diagnosed by two senior dermatologists; history of disease longer than 1 year; 2. Aged 18-60 years; 3. Right-handedness; 4. No contraindications to fMRI examination (metal implants, claustrophobia, etc.); 5. No combined serious primary diseases of the heart, brain, liver, kidney, hematopoietic system or neurological or psychiatric diseases; 6. Signed informed consent form. Control group: 1. There was no history of rosacea and related symptoms; 2. Aged 18-60 years; 3. Open your right hand; 4. No contraindications of fMRI examination (metal implantation, claustrophobia, etc.); 5. No serious primary diseases of the heart, brain, liver, kidney or hematopoietic system, or neurological or mental diseases are involved; 6. Voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: Experiment group: 1. Have taken pesticides, poisons or other substances that may cause damage to the central nervous system, have a history of alcohol and drug abuse; 2. Have taken antidepressants or other psychiatric drugs on their own; 3. Who have taken non-psychiatric oral medications such as minocycline, pregabalin, carvedilol, etc. orally within 2 weeks; 4. Patients who are pregnant or breastfeeding. Control group: 1. Pregnant and lactating patients; 2. Serious asymmetry of skull anatomy or clear lesions found in the scan; 3. Unconsciousness, unable to express discomfort independently or unable to cooperate with the completion of this study.

Design outcomes

Primary

MeasureTime frame
functional connectivity;Trait anxiety;depressive score;

Secondary

MeasureTime frame
amplitude of low-frequency fluctuation;gray matter volume;Scores of The Big-Five;Stigma questionnaire;Resilience Scale;Cognitive Emotion Regulation Questionnaire;Dermatology Quality of Life questionnaire;Social Appearance Anxiety Scale;Social Avoidance and Distress Scale;

Countries

China

Contacts

Public ContactJiang Xian

West China Hospital, Sichuan University

jiangxian@scu.edu.cn+86 189 8060 1693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026